Amgen 2012 Annual Report Download - page 94

Download and view the complete annual report

Please find page 94 of the 2012 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 150

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150

87
Exhibit No. Description
10.53 Supply Agreement between Amgen Inc. and Takeda Pharmaceutical Company Limited dated February 1,
2008 (with certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the
quarter ended March 31, 2008 on May 12, 2008 and incorporated herein by reference.)
10.54* Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited dated May 10, 2002
(with certain confidential information deleted therefrom) and Amendment No. 1, effective as of June 9,
2003, to Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited (with
certain confidential information deleted therefrom).
10.55 Integrated Facilities Management Services Agreement, dated February 4, 2009, between Amgen Inc. and
Jones Lang LaSalle Americas, Inc. (with certain confidential information deleted therefrom) (Previously
filed as an exhibit to Form 10-K for the year ended December 31, 2008 on February 27, 2009.), as amended
by Amendment Number 1 dated March 31, 2010 (with certain confidential information deleted therefrom),
Amendment Number 2 dated May 12, 2011 (as corrected by the Letter Agreement) (with certain confidential
information deleted therefrom), and Letter Agreement dated July 19, 2011. (Filed as an exhibit to Form
10-Q for the quarter ended June 30, 2011 on August 8, 2011 and incorporated herein by reference.)
10.56 Amendment Number 3, dated July 1, 2011, to the Integrated Facilities Management Services Agreement,
dated February 4, 2009, between Amgen Inc. and Jones Lang LaSalle Americas, Inc. (Filed as an exhibit
to Form 10-Q for the quarter ended September 30, 2011 on November 4, 2011 and incorporated herein by
reference.)
10.57 Collaboration Agreement dated July 27, 2009 between Amgen Inc. and Glaxo Group Limited, a wholly
owned subsidiary of GlaxoSmithKline plc (with certain confidential information deleted therefrom). (Filed
as an exhibit to Form 10-Q for the quarter ended September 30, 2009 on November 6, 2009 and incorporated
herein by reference.)
10.58* Amendment Number 1, dated as of January 24, 2012, to Collaboration Agreement dated July 27, 2009
between Amgen Inc. and Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc.
10.59 Expansion Agreement dated July 27, 2009 between Amgen Inc. and Glaxo Group Limited, a wholly owned
subsidiary of GlaxoSmithKline plc (with certain confidential information deleted therefrom). (Filed as an
exhibit to Form 10-Q for the quarter ended September 30, 2009 on November 6, 2009 and incorporated
herein by reference.)
10.60 Amendment Number 1, dated September 20, 2010, to Expansion Agreement dated July 27, 2009 between
Amgen Inc. and Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc (with certain
confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter ended
September 30, 2010 on November 8, 2010 and incorporated herein by reference.)
10.61* Amendment Number 2, dated as of January 24, 2012, to Expansion Agreement dated July 27, 2009 between
Amgen Inc. and Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc.
10.62 Sourcing and Supply Agreement, dated November 15, 2011, by and between Amgen USA Inc, a wholly
owned subsidiary of Amgen Inc., and DaVita Inc. (with certain confidential information deleted
therefrom). (Filed as an exhibit to Form 10-K for the year ended December 31, 2011 on February 29,
2012 and incorporated herein by reference.)
10.63* Amendment Number 1 to Sourcing and Supply Agreement, effective as of January 1, 2013, by and
between Amgen USA Inc., a wholly owned subsidiary of Amgen Inc., and DaVita Healthcare Partners
Inc. f/k/a DaVita Inc. (with certain confidential information deleted therefrom).
10.64 Collaboration Agreement dated March 30, 2012 by and between Amgen Inc. and AstraZeneca
Collaboration Ventures, LLC, a wholly owned subsidiary of AstraZeneca Pharmaceuticals LP (with
certain confidential information deleted therefrom). (Filed as an exhibit to Form 10-Q for the quarter
ended March 31, 2012 on May 8, 2012 and incorporated herein by reference.)
21* Subsidiaries of the Company.
23 Consent of the Independent Registered Public Accounting Firm. The consent is set forth on pages 90
and 91 of this Annual Report on Form 10-K.
24 Power of Attorney. The Power of Attorney is set forth on page 92 of this Annual Report on Form 10-K.